April 1 (Reuters) - The U.S. Food and Drug Administrationfound contamination of drug ingredients manufactured at aGlaxoSmithKline Plc plant in Ireland and said thecompany did not take sufficient action to resolve the problems.
The news comes just days after GSK said it was recalling allsupplies of its over-the-counter weight-loss drug in the UnitedStates and Puerto Rico, after concerns that bottles had beentampered with.
In a warning letter dated March 18, the FDA said the companydid not fully investigate a list of objectional conditions theregulator sent after its inspection of the manufacturingfacility at Cork, Ireland in October.
The FDA said its investigator found that a certain drugingredient, the name of which was not disclosed, wascontaminated with material from the facility's pharmaceuticalwaste tank. (http://link.reuters.com/xah28v) (Reporting by Vrinda Manocha in Bangalore; Editing by MajuSamuel)